Thu Pham and Zizheng Li, both PhD candidates in UCSF's Pharmaceutical Sciences and Pharmacogenomics program (PSPG), are recipients of the 2026 Predoctoral Fellowship in Translational Medicine from the PhRMA Foundation.
Established in 1965, the PhRMA Foundation invests in promising researchers and their novel ideas to foster biopharmaceutical innovation and value-driven health care. The Foundation catalyzes the careers of promising researchers through competitive, peer-reviewed grants and fellowships in the fields of drug delivery, drug discovery, translational medicine, and value assessment and health outcomes research.
Thu Pham
Pharmaceutical Sciences and Pharmacogenomics PhD program
Graduate Adviser: Yin Shen, PhD
Thu is receiving support from the PhRMA Foundation for her research into understanding why some cancer patients develop severe nerve damage from chemotherapy while others do not.
Zizheng Li
Pharmaceutical Sciences and Pharmacogenomics PhD program
Graduate Advisers: Lani Wu, PhD and Steven Altschuler, PhD
Zizheng received the PhRMA Foundation fellowship for his research on amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that destroys nerve cells that control movement.
The PhRMA Foundation is currently accepting letters of intent (LOIs) or applications through Oct. 30, 2026 for predoctoral and postdoctoral fellowships in drug discovery, drug delivery, translational medicine, and value assessment and health outcomes. Find full details on the PhRMA Foundation website.